Published in Pharma Law Weekly, June 2nd, 2009
In discussions with analysts, the company reports that it has crossed an important plateau and is now cash positive. Quarter over quarter (2008/2009), revenues are up 14.5% to $1,138,882. Management reports that health measurement indicators are all positive. Operating expenses are down 11.4%, Gross Profits are up 5.6% and income has gone from a $76,000 loss to a $41,000 profit.
“This is all good,” reports CEO Tony Shupin. “Our business model is working, our sales are growing in spite...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.